Prognostic and theranostic impact of molecular subtypes and immune classifications in renal cell cancer (RCC) and colorectal cancer (CRC)

OncoImmunology

Volumn 4, Issue 12, 2015, Pages

  Becht, Etienne ^a,b,c   Giraldo, Nicolas A ^a,b,c   Beuselinck, Benoit ^d,e   Job, Sylvie ^f   Marisa, Laetitia ^f   Vano, Yann ^a,b,c,g   Oudard, Stéphane ^b,g   Zucman Rossi, Jessica ^d,g   Laurent Puig, Pierre ^b,g   Sautès Fridman, Catherine ^a,b,c   de Reyniès, Aurélien ^f   Fridman, Wolf Herman ^a,b,c,g  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d Université Paris 13   (France)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^f Programme Cartes d'Identité des Tumeurs Ligue Nationale Contre le Cancer   (France)

^g HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Cancer molecular subtypes; colorectal cancer; immune classification; prognostic and theranostic markers; renal cell cancer; tumor microenvironment

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; GEFITINIB; IMATINIB; K RAS PROTEIN; PERTUZUMAB; SUNITINIB; TRANSCRIPTOME; TRANSFORMING GROWTH FACTOR BETA; TRASTUZUMAB; VEMURAFENIB;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CHROMOSOMAL INSTABILITY; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL CANCER; DOWN REGULATION; GENE MUTATION; GENE TRANSLOCATION; HUMAN; IMMUNE RESPONSE; KIDNEY CANCER; LUNG CANCER; MICROSATELLITE INSTABILITY; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SARCOMATOID CARCINOMA; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84944583888     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1049804     Document Type: Article

References (37)

1. B.Vogelstein, N.Papadopoulos, V.E.Velculescu, S.Zhou, L.A.J.Diaz, K.W.Kinzler. Cancer genome landscapes. Science 2013; 339:1546-58; PMID:23539594; http://dx.doi.org/10.1126/science.1235122
2. W.Fridman, F.Pagès, C.Sautès-Fridman, J.Galon. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012; 12:298-306; PMID:22419253; http://dx.doi.org/10.1038/nrc3245
3. P.B.Chapman, A.Hauschild, C.Robert, J.B.Haanen, P.Ascierto, J.Larkin, R.Dummer, C.Garbe, A.Testori, M.Maio, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507-16; PMID:21639808; http://dx.doi.org/10.1056/NEJMoa1103782
4. R.Rosell, E.Carcereny, R.Gervais, A.Vergnenegre, B.Massuti, E.Felip, R.Palmero, R.Garcia-Gomez, C.Pallares, J.M.Sanchez, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13:239-46; PMID:22285168; http://dx.doi.org/10.1016/S1470-2045(11)70393-X
5. M.Maemondo, A.Inoue, K.Kobayashi, S.Sugawara, S.Oizumi, H.Isobe, A.Gemma, M.Harada, H.Yoshizawa, I.Kinoshita, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362:2380-8; PMID:20573926; http://dx.doi.org/10.1056/NEJMoa0909530
6. E.Weisberg, P.W.Manley, S.W.Cowan-Jacob, A.Hochhaus, J.D.Griffin. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 2007; 7:345-56; PMID:17457302; http://dx.doi.org/10.1038/nrc2126
7. M.J.Piccart-Gebhart, M.Procter, B.Leyland-Jones, A.Goldhirsch, M.Untch, I.Smith, L.Gianni, J.Baselga, R.Bell, C.Jackisch, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353:1659-72; PMID:16236737; http://dx.doi.org/10.1056/NEJMoa052306
8. C.S.Karapetis, S.Khambata-Ford, D.J.Jonker, C.J.O'Callaghan, D.Tu, N.C.Tebbutt, R.J.Simes, H.Chalchal, J.D.Shapiro, S.Robitaille, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359:1757-65; PMID:18946061; http://dx.doi.org/10.1056/NEJMoa0804385
9. B.Beuselinck, S.Job, E.Becht, A.Karadimou, V.Verkarre, G.Couchy, N.Giraldo, N.Rioux-Leclercq, V.Molinié, M.Sibony, et al. Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting. Clin Cancer Res 2015; 21:1329-39; PMID:25583177
10. G.S.Papaetis, K.N.Syrigos. Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies. BioDrugs 2009; 23:377-89; PMID:19894779
11. The Cancer Genome Atlas. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487:330-7; PMID:22810696; http://dx.doi.org/10.1038/nature11252
12. A.Schlicker, G.Beran, C.M.Chresta, G.McWalter, A.Pritchard, S.Weston, S.Runswick, S.Davenport, K.Heathcote, D.A.Castro, et al. Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines. BMC Med Genomics 2012; 5:66; PMID:23272949; http://dx.doi.org/10.1186/1755-8794-5-66
13. A.Sadanandam, C.A.Lyssiotis, K.Homicsko, E.A.Collisson, W.J.Gibb, S.Wullschleger, L.C.Ostos, W.A.Lannon, C.Grotzinger, M.Del Rio, et al. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med 2013; 19:619-25; PMID:23584089; http://dx.doi.org/10.1038/nm.3175
14. F.De Sousa E Melo, X.Wang, M.Jansen, E.Fessler, A.Trinh, L.P.M.H.de Rooij, J.H.de Jong, O.J.de Boer, R.van Leersum, M.F.Bijlsma, et al. Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nat Med 2013; 19:614-8; PMID:23584090; http://dx.doi.org/10.1038/nm.3174
15. E.Budinska, V.Popovici, S.Tejpar, G.D'Ario, N.Lapique, K.O.Sikora, A.F.Di Narzo, P.Yan, J.G.Hodgson, S.Weinrich, et al. Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer. J Pathol 2013; 231:63-76; PMID:23836465; http://dx.doi.org/10.1002/path.4212
16. L.Marisa, A.de Reyniès, A.Duval, J.Selves, M.P.Gaub, L.Vescovo, M.C.Etienne-Grimaldi, R.Schiappa, D.Guenot, M.Ayadi, et al. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PLoS Med 2013; 10:e1001453; PMID:23700391; http://dx.doi.org/10.1371/journal.pmed.1001453
17. E.J.Lipson, W.H.Sharfman, C.G.Drake, I.Wollner, J.M.Taube, R.A.Anders, H.Xu, S.Yao, A.Pons, L.Chen, et al. Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res 2013; 19:462-8; PMID:23169436; http://dx.doi.org/10.1158/1078-0432.CCR-12-2625
18. L.Zhang, J.R.Conejo-Garcia, D.Katsaros, P.A.Gimotty, M.Massobrio, G.Regnani, A.Makrigiannakis, H.Gray, K.Schlienger, M.N.Liebman, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003; 348:203-13; PMID:12529460; http://dx.doi.org/10.1056/NEJMoa020177
19. J.Galon, A.Costes, F.Sanchez-Cabo, A.Kirilovsky, B.Mlecnik, C.Lagorce-Pagès, M.Tosolini, M.Camus, A.Berger, P.Wind, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313:1960-1964; PMID:17008531; http://dx.doi.org/10.1126/science.1129139
20. J.Galon, F.Pagès, F.M.Marincola, H.K.Angell, M.Thurin, A.Lugli, I.Zlobec, A.Berger, C.Bifulco, G.Botti, et al. Cancer classification using the immunoscore: a worldwide task force. J Transl Med 2012; 10:205; PMID:23034130; http://dx.doi.org/10.1186/1479-5876-10-205
21. R.S.Herbst, J.Soria, M.Kowanetz, G.D.Fine, O.Hamid, M.S.Gordon, J.A.Sosman, D.F.McDermott, J.D.Powderly, S.N.Gettinger, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014; 515:563-7; PMID:25428504; http://dx.doi.org/10.1038/nature14011
22. J.M.Taube, A.Klein, J.R.Brahmer, H.Xu, X.Pan, J.H.Kim, L.Chen, D.M.Pardoll, S.L.Topalian, R.A.Anders. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to Anti-PD-1 therapy. Clin Cancer Res 2014; 20:5064-74; PMID:24714771; http://dx.doi.org/10.1158/1078-0432.CCR-13-3271
23. M.Dieu-Nosjean, J.Goc, N.A.Giraldo, C.Sautes-Fridman, W.H.Fridman. Tertiary lymphoid structures in cancer and beyond. Trends Immunol 2014; 35:571-580; PMID:25443495; http://dx.doi.org/10.1016/j.it.2014.09.006
24. L.Maldonado, J.E.Teague, M.P.Morrow, I.Jotova, T.C.Wu, C.Wang, C.Desmarais, J.D.Boyer, B.Tycko, H.S.Robins, et al. Intramuscular therapeutic vaccination targeting HPV16 induces T cell responses that localize in mucosal lesions. Sci Transl Med 2014; 6:221ra13; PMID:24477000; http://dx.doi.org/10.1126/scitranslmed.3007323
25. E.R.Lutz, A.A.Wu, E.Bigelow, R.Sharma, G.Mo, K.Soares, S.Solt, A.Dorman, A.Wamwea, A.Yager, et al. Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation. Cancer Immunol Res 2014; 2:616-31; PMID:24942756; http://dx.doi.org/10.1158/2326-6066.CIR-14-0027
26. C.Badoual, S.Hans, N.Merillon, C.Van Ryswick, P.Ravel, N.Benhamouda, E.Levionnois, M.Nizard, A.Si-Mohamed, N.Besnier, et al. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res 2013; 73:128-38; PMID:23135914; http://dx.doi.org/10.1158/0008-5472.CAN-12-2606
27. D.W.Scott, F.C.Chan, F.Hong, S.Rogic, K.L.Tan, B.Meissner, S.Ben-Neriah, M.Boyle, R.Kridel, A.Telenius, et al. Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma. J Clin Oncol 2013; 31:692-700; PMID:23182984; http://dx.doi.org/10.1200/JCO.2012.43.4589
28. J.J.F.Muris, C.J.L.M.Meijer, S.A.G.M.Cillessen, W.Vos, J.A.Kummer, B.A.Bladergroen, M.J.Bogman, M.A.MacKenzie, N.M.Jiwa, L.H.Siegenbeek van Heukelom, et al. Prognostic significance of activated cytotoxic T-lymphocytes in primary nodal diffuse large B-cell lymphomas. Leukemia 2004; 18:589-96; PMID:14712286; http://dx.doi.org/10.1038/sj.leu.2403240
29. O.Nakano, M.Sato, Y.Naito, K.Suzuki, S.Orikasa, M.Aizawa, Y.Suzuki, I.Shintaku, H.Nagura, H.Ohtani. Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res 2001; 61:5132-6; PMID:11431351
30. N.Giraldo, E.Becht, F.Pages, G.P.Skliris, V.Verkarre, Y.Vano, A.Mejean, N.Saint-Aubert, L.Lacroix, I.Natario, et al. Orchestration and prognostic significance of immune checkpoints in the microenvironment of primary and metastatic renal cell cancer. Clin Cancer Res 2015; 21:3031-40; PMID:25688160
31. R.Remark, M.Alifano, I.Cremer, A.Lupo, M.Dieu-Nosjean, M.Riquet, L.Crozet, H.Ouakrim, J.Goc, A.Cazes, et al. Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: influence of tumor origin. Clin Cancer Res 2013; 19:4079-4091; PMID:23785047; http://dx.doi.org/10.1158/1078-0432.CCR-12-3847
32. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013; 499:43-9; PMID:23792563; http://dx.doi.org/10.1038/nature12222
33. N.Halama, S.Michel, M.Kloor, I.Zoernig, A.Benner, A.Spille, T.Pommerencke, D.M.von Knebel, G.Folprecht, B.Luber, et al. Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy. Cancer Res 2011; 71:5670-7; PMID:21846824; http://dx.doi.org/10.1158/0008-5472.CAN-11-0268
34. E.Becht, J.Goc, C.Germain, N.A.Giraldo, M.Dieu-Nosjean, C.Sautès-Fridman, W.H.Fridman. Shaping of an effective immune microenvironment to and by cancer cells. Cancer Immunol Immunother 2014 63:991-7; PMID:25112529; http://dx.doi.org/10.1007/s00262-014-1590-3
35. G.Bindea, B.Mlecnik, M.Tosolini, A.Kirilovsky, M.Waldner, A.C.Obenauf, H.Angell, T.Fredriksen, L.Lafontaine, A.Berger, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 2013; 39:782-95; PMID:24138885; http://dx.doi.org/10.1016/j.immuni.2013.10.003
36. B.Mlecnik, G.Bindea, H.K.Angell, M.S.Sasso, A.C.Obenauf, T.Fredriksen, L.Lafontaine, A.M.Bilocq, A.Kirilovsky, M.Tosolini, et al. Functional network pipeline reveals genetic determinants associated with in situ lymphocyte proliferation and survival of cancer patients. Sci Transl Med 2014; 6:228ra37; PMID:24648340; http://dx.doi.org/10.1126/scitranslmed.3007240
37. M.Camus, M.Tosolini, B.Mlecnik, F.Pagès, A.Kirilovsky, A.Berger, A.Costes, G.Bindea, P.Charoentong, P.Bruneval, et al. Coordination of intratumoral immune reaction and human colorectal cancer recurrence. Cancer Res 2009; 69:2685-93; PMID:19258510; http://dx.doi.org/10.1158/0008-5472.CAN-08-2654